ChromaTan and Landmark Bio Awarded National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) Grant to Advance Intensified Recombinant Adeno-Associated Virus (AAV) Production Process
Grant allows ChromaTan and Landmark Bio to create a scalable, cost-effective, and accessible platform for the manufacturing and characterization of AAV-based gene therapy vectors. Project developed with award from NIIMBL and financial assistance from the National Institute of Standards and Technology.
Landmark Bio Signs Multi-Year Agreement to Manufacture Galapagos’ Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care
Landmark Bio will serve as strategic point-of-care manufacturing partner for Galapagos’ CAR-T product candidates in the Boston area
Landmark Bio Partners With InnDura Therapeutics to Advance Immune Cell Therapy Research
Landmark Bio will serve as strategic partner in the development and manufacturing of InnDura’s pipeline products
Landmark Bio Unveils New State-of-the-Art Full-Spectrum Biomanufacturing Innovation Center
New 44,000 square-foot fully integrated facility for development, manufacturing and testing of cell and gene therapies in Watertown, Massachusetts, offers end-to-end capabilities and onestop manufacturing solutions
Landmark Bio Appoints Gregg Nyberg, Ph.D., as Chief Technology Officer and Michael Covington as Chief Quality and Regulatory Officer
Newest members of Landmark Bio’s executive team bring decades of industry leadership and expertise in drug development and biomanufacturing
Introducing Landmark Bio and Appointment of Ran Zheng as CEO
Zheng will lead the construction of the new, state-of-the-art biomanufacturing facility that kicks off today (July 29) in Watertown, MA and will begin opening in 2022.